Friday, November 20, 2009
Watch Dr Meade interview Dr Duane Graveline on statin drugs and Cholesterol
Watch part one and part two of this video on Inside Medicine titled Myths on Cholesterol wherein Dr Meade an orthopedic surgeon interviews the SpaceDoc - Dr Duane Graveline.
Dr John Briffa on ezetimibe (Zetia)
More bad news for the makers (and takers) of cholesterol-reducing drug ezetimibe (Zetia) http://www.drbriffa.com
Posted By Dr John Briffa On November 16, 2009
Previously, I have written about the drug combination of simvastatin and ezetimibe (sold as Vytorin in the US). Both of these drugs reduce cholesterol, but through different mechanisms. Taken together, these drugs do do a good job of reducing cholesterol levels And we all know that the lower we get the cholesterol levels down the better, right? Well, actually, results show that Vytorin [1] did not work to halt the progression of the ‘plaques’ that gum up arteries and can precipitate heart attacks and strokes.
And then another thing is that giving people simvastatin and ezetimibe is associated with an increased risk of [2] death due to cancer. This finding was inexplicably waved away by scientists as a [3] chance finding (even though the statistics showed that the finding was very unlikely to be due to chance).
Anyway, this week sees more bad news for the manufacturers of Vytorin and also those who take it. The New England Journal of Medicine has just published a study in which individuals on a statin were additionally treated with ezetimibe or niacin (vitamin B3) over 14 months [1]. All of the individuals in the trial had either been diagnosed with heart disease or were deemed to be at high risk of this condition.
The researchers measured a number of parameters including:
LDL-cholesterol (a form of cholesterol said to be associated with a higher risk of cardiovascular disease)
HDL-cholesterol (a form of cholesterol said to be associated with a lower risk of cardiovascular disease)
Triglyceride levels (a form of blood fat said to be associated with higher risk of cardiovascular disease)
Carotid artery intima thickness (the thickness of the wall of the major blood vessel supplying blood to the head – increased thickness is generally taken as a sign of worsening cardiovascular disease risk)
In the group taking a statin and ezetimibe, LDL, HDL and triglyceride levels went down.
In the group taking a statin and niacin, LDL and triglyceride levels went down, and HDL levels went up.
On paper, at this point, the group taking the niacin and statin fared better. However, more important than these results were those relating to the carotid artery intima thickness. Guess what? The group taking the niacin did better than the group taking ezetimibe on this score too.
One other outcome the researchers kept tabs on was ‘major cardiovascular events’ such as heart attacks and strokes. Here again, the niacin group fared better – 1 per cent of them had such an event compared to 5 per cent in the group taking ezetimibe.
The New York Times reports [4] here that Dr Peter Kim, the president of Merck Research Laboratories (makers of ezetimibe) claimed that the study was limited because it did not compare the groups of patients taking a statin and a second drug to a placebo group. He also claims that a drug’s ability to improve artery-wall thickness has not been proved to automatically correlate with a reduction in heart attacks. Moreover he stated that ezetimibe lowers bad cholesterol and lowering bad cholesterol is a “known good”.
Ezetimibe has been licenced on the basis of its ability to reduce LDL-cholesterol – something that is referred to as a ‘surrogate marker’. So, Merck it seems that Merck is happy for its drug to be sold and promoted on the basis of one surrogate marker (reduced cholesterol), but none-too-keen for its drug to be criticised on the basis of another surrogate measure (carotid artery intima thickness).
Dr Kim also describes a reduction in bad (LDL) cholesterol as a “known good”. However, the new England Journal of Medicine study found that lower levels of LDL cholesterol were actually associated with an increase in carotid artery intima thickness. And never mind this, do we really think that just because something reduces LDL cholesterol levels, that has to be a good thing. I mean, if arsenic and cyanide were found to reduce LDL cholesterol levels, would that mean we should all be taking arsenic and cyanide every day?
The New York Times article also quotes Dr James Stein, professor at the University of Wisconsin medical school, who points out that as far as ezetimibe is concerned, “there is not a shred of evidence that it does anything good for blood vessels or heart disease.”
References:
1. Taylor AJ, et al. Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness NEJM 15th November 2009 [epub ahead of print]
--------------------------------------------------------------------------------
Article printed from Dr Briffa’s Blog: http://www.drbriffa.com
URL to article: http://www.drbriffa.com/blog/2009/11/16/more-bad-news-for-the-makers-and-takers-of-cholesterol-reducing-drug-ezetimibe-zetia/
URLs in this post:
[1] did not work: http://www.drbriffa.com/blog/2008/01/28/trial-results-forced-out-of-drug-company-support-the-concept
-that-cholesterol-may-not-cause-cardiovascular-disease/
[2] death due to cancer: http://www.drbriffa.com/blog/2008/07/23/cholesterol-lowering-combination-found-to-have-limited-benef
it-again-and-now-is-linked-with-increased-risk-of-cancer/
[3] chance finding: http://www.drbriffa.com/blog/2008/09/03/is-it-right-for-scientists-to-put-the-links-between-choleste
rol-reducing-medication-and-cancer-down-to-chance/
[4] here: http://www.nytimes.com/2009/11/16/health/research/16heart.html
Posted By Dr John Briffa On November 16, 2009
Previously, I have written about the drug combination of simvastatin and ezetimibe (sold as Vytorin in the US). Both of these drugs reduce cholesterol, but through different mechanisms. Taken together, these drugs do do a good job of reducing cholesterol levels And we all know that the lower we get the cholesterol levels down the better, right? Well, actually, results show that Vytorin [1] did not work to halt the progression of the ‘plaques’ that gum up arteries and can precipitate heart attacks and strokes.
And then another thing is that giving people simvastatin and ezetimibe is associated with an increased risk of [2] death due to cancer. This finding was inexplicably waved away by scientists as a [3] chance finding (even though the statistics showed that the finding was very unlikely to be due to chance).
Anyway, this week sees more bad news for the manufacturers of Vytorin and also those who take it. The New England Journal of Medicine has just published a study in which individuals on a statin were additionally treated with ezetimibe or niacin (vitamin B3) over 14 months [1]. All of the individuals in the trial had either been diagnosed with heart disease or were deemed to be at high risk of this condition.
The researchers measured a number of parameters including:
LDL-cholesterol (a form of cholesterol said to be associated with a higher risk of cardiovascular disease)
HDL-cholesterol (a form of cholesterol said to be associated with a lower risk of cardiovascular disease)
Triglyceride levels (a form of blood fat said to be associated with higher risk of cardiovascular disease)
Carotid artery intima thickness (the thickness of the wall of the major blood vessel supplying blood to the head – increased thickness is generally taken as a sign of worsening cardiovascular disease risk)
In the group taking a statin and ezetimibe, LDL, HDL and triglyceride levels went down.
In the group taking a statin and niacin, LDL and triglyceride levels went down, and HDL levels went up.
On paper, at this point, the group taking the niacin and statin fared better. However, more important than these results were those relating to the carotid artery intima thickness. Guess what? The group taking the niacin did better than the group taking ezetimibe on this score too.
One other outcome the researchers kept tabs on was ‘major cardiovascular events’ such as heart attacks and strokes. Here again, the niacin group fared better – 1 per cent of them had such an event compared to 5 per cent in the group taking ezetimibe.
The New York Times reports [4] here that Dr Peter Kim, the president of Merck Research Laboratories (makers of ezetimibe) claimed that the study was limited because it did not compare the groups of patients taking a statin and a second drug to a placebo group. He also claims that a drug’s ability to improve artery-wall thickness has not been proved to automatically correlate with a reduction in heart attacks. Moreover he stated that ezetimibe lowers bad cholesterol and lowering bad cholesterol is a “known good”.
Ezetimibe has been licenced on the basis of its ability to reduce LDL-cholesterol – something that is referred to as a ‘surrogate marker’. So, Merck it seems that Merck is happy for its drug to be sold and promoted on the basis of one surrogate marker (reduced cholesterol), but none-too-keen for its drug to be criticised on the basis of another surrogate measure (carotid artery intima thickness).
Dr Kim also describes a reduction in bad (LDL) cholesterol as a “known good”. However, the new England Journal of Medicine study found that lower levels of LDL cholesterol were actually associated with an increase in carotid artery intima thickness. And never mind this, do we really think that just because something reduces LDL cholesterol levels, that has to be a good thing. I mean, if arsenic and cyanide were found to reduce LDL cholesterol levels, would that mean we should all be taking arsenic and cyanide every day?
The New York Times article also quotes Dr James Stein, professor at the University of Wisconsin medical school, who points out that as far as ezetimibe is concerned, “there is not a shred of evidence that it does anything good for blood vessels or heart disease.”
References:
1. Taylor AJ, et al. Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness NEJM 15th November 2009 [epub ahead of print]
--------------------------------------------------------------------------------
Article printed from Dr Briffa’s Blog: http://www.drbriffa.com
URL to article: http://www.drbriffa.com/blog/2009/11/16/more-bad-news-for-the-makers-and-takers-of-cholesterol-reducing-drug-ezetimibe-zetia/
URLs in this post:
[1] did not work: http://www.drbriffa.com/blog/2008/01/28/trial-results-forced-out-of-drug-company-support-the-concept
-that-cholesterol-may-not-cause-cardiovascular-disease/
[2] death due to cancer: http://www.drbriffa.com/blog/2008/07/23/cholesterol-lowering-combination-found-to-have-limited-benef
it-again-and-now-is-linked-with-increased-risk-of-cancer/
[3] chance finding: http://www.drbriffa.com/blog/2008/09/03/is-it-right-for-scientists-to-put-the-links-between-choleste
rol-reducing-medication-and-cancer-down-to-chance/
[4] here: http://www.nytimes.com/2009/11/16/health/research/16heart.html
Wednesday, November 11, 2009
Statin Drugs and Mitochondrial Damage
Duane Graveline, the Spacedoc, introduces the topic of statin drug side effects this way...
Any of those sound familiar as symptoms you have seen or heard of in someone that you know who is on the statin drug or have you experienced them yourself as a user. I did for much too long. Yet the prescribed drugs did not do what they were touted to do - prevent cardiovascular disease or heart attack in my case. I will admit they did reduce my cholesterol. Enough so that my cardiologists were tickled pink. I felt I was doing more to prevent them from having a coronary than myself. With 'dumb, fat, and happy' low cholesterol I had five heart attacks and intestinal cancer (an increased risk side effect of statin usage). Don't know how the cardiologists and GPs who prescribed them, and were so entheusiastically promoting their benefits and likely taking the miracle drug themselves are doing. Hopefully they are faring better than I did.
Read Dr Gravline's full series of articles on Statin Drugs and Mitochondrial Damage here.
"Tens of thousands of statin users have complained to their doctors of weakness, instability, easy fatigue, muscle aches and pains, burning of their extremities, depression, personality change and faulty memory, ... "
Any of those sound familiar as symptoms you have seen or heard of in someone that you know who is on the statin drug or have you experienced them yourself as a user. I did for much too long. Yet the prescribed drugs did not do what they were touted to do - prevent cardiovascular disease or heart attack in my case. I will admit they did reduce my cholesterol. Enough so that my cardiologists were tickled pink. I felt I was doing more to prevent them from having a coronary than myself. With 'dumb, fat, and happy' low cholesterol I had five heart attacks and intestinal cancer (an increased risk side effect of statin usage). Don't know how the cardiologists and GPs who prescribed them, and were so entheusiastically promoting their benefits and likely taking the miracle drug themselves are doing. Hopefully they are faring better than I did.
Read Dr Gravline's full series of articles on Statin Drugs and Mitochondrial Damage here.
Monday, November 9, 2009
Dr. Davis on Vitamin D
Addessing the question "What is a healthy vitamin D blood level?" Dr Davis makes some valuable points.
A previous post here from Dr Davis, "Another reason not to get sick in a hospital", also addresses vitamin D but with a different focus.
Vitamin D is so important for so many reasons that I recommend reading both of his articles in full. Please click on the links above.
A previous post here from Dr Davis, "Another reason not to get sick in a hospital", also addresses vitamin D but with a different focus.
Vitamin D is so important for so many reasons that I recommend reading both of his articles in full. Please click on the links above.
Sunday, November 8, 2009
Horrible Hiney(H1n1) - Mortality in perspective
I just spent a week in Calgary where it was much cooler than my body is accustom to but the H1N1 panic was heated up to a fever pitch which was hard to explain in my mind.
My son emailed me a link to Michael Paukner's flickr site that has a chart that helps put the magnitude of the threat in perspective.
My son emailed me a link to Michael Paukner's flickr site that has a chart that helps put the magnitude of the threat in perspective.
Go to this link to see it with better detail.
Note the H1N1 entry in red near the middle of the chart. Kind of dwarfs other health risks such as cardiovascular disease and cancer - right? I wonder where deaths due to water born diseases would lie on the chart. That's one we could actually do something significant on and reduce mortality especially among the young and most vulnerable. I'm convinced that H1N1 is a scare of the affluent.
Subscribe to:
Posts (Atom)